P457: Complications and disease recurrence after primary ileocecal resection in paediatric Crohn’s disease: a multicentre cohort analysisECCO '16 Amsterdam
2016
P458: Multidisciplinary working when developing the UK inflammatory bowel disease standards and IBD auditECCO '16 Amsterdam
2016
P459: Risk of relapse after azathioprine discontinuation in inflammatory bowel disease patients in maintained remissionECCO '16 Amsterdam
2016
P461: Clinical benefit of adalimumab after surgery in the treatment of complex perianal Crohn’s disease: a tertiary referral centre experienceECCO '16 Amsterdam
2016
P462: Adalimumab improves treatment satisfaction with medication and work productivity amongst patients with ulcerative colitis in a clinical practice setting: results from INSPIRADAECCO '16 Amsterdam
2016
P463: Combination therapy of fresh faecal microbial transplantation and antibiotics for ulcerative colitisECCO '16 Amsterdam
2016
P464: Assessing medication adherence in patients with inflammatory bowel disease: what do we choose, self-adherence scales or pharmacy rates?ECCO '16 Amsterdam
2016
P465: Indication-specific feasibility assessment of a placebo-controlled randomised mesalazine withdrawal study for paediatric patients with ulcerative colitisECCO '16 Amsterdam
2016
P466: Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumour necrosis factor alpha therapy: a prospective single-centre open-label studyECCO '16 Amsterdam
2016
P467: The validation of the Crohn’s and Ulcerative Colitis Questionnaire–12 Plus (CUCQ-12 plus): a short quality-of-life measure for inflammatory bowel diseaseECCO '16 Amsterdam
2016
P468: Long-term efficacy and safety of thiopurine in biologic-naïve Japanese patients with ulcerative colitis: a multicentre retrospective studyECCO '16 Amsterdam
2016
P469: Changes in peripheral blood lymphocyte subsets induced by azathioprine in Crohn’s disease patientsECCO '16 Amsterdam
2016
P470: Early change in faecal calprotectin during anti-TNFα initiation is strongly predictive of outcome in Crohn’s diseaseECCO '16 Amsterdam
2016
P471: Safety analysis of multimatrix mesalazine amongst patients with ulcerative colitis or recurrent diverticulitis ≥ 55 years of ageECCO '16 Amsterdam
2016
P472: Faecal calprotectin as a biomarker of early mucosal healing in patients with ulcerative colitis naïve to adalimumab treatmentECCO '16 Amsterdam
2016
P473: Clinical and biochemical factors that influence response in inflammatory disease patients receiving tacrolimusECCO '16 Amsterdam
2016
P474: Assessing the position of systemic tacrolimus in the treatment of inflammatory bowel disease: systematic review and meta-analysisECCO '16 Amsterdam
2016